Chongqing

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Lung cancer2 trials

Phase

• Phase 11 trial
• Phase 31 trial

Status

• Active, not recruiting2 trials

Lead sponsor

• ArriVent BioPharma, Inc.2 trials

Running trials

• Active, not recruiting

  Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

  NCT05607550· Phase 3· ArriVent BioPharma, Inc.· Source

• Active, not recruiting

  Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

  NCT05364073· Phase 1· ArriVent BioPharma, Inc.· Source